Eric Whitman
Overview
Explore the profile of Eric Whitman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
832
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chesney J, Lewis K, Kluger H, Hamid O, Whitman E, Thomas S, et al.
J Immunother Cancer
. 2023 Jan;
10(12).
PMID: 36600653
Background: Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed objective response...
2.
Cafardi J, Miller C, Terebelo H, Tewell C, Benzaquen S, Park D, et al.
JAMA Netw Open
. 2022 Dec;
5(12):e2242918.
PMID: 36469321
Importance: The morbidity and mortality associated with COVID-19 remain high despite advances in standard of care therapy, and the role of anti-inflammatory agents that inhibit the interleukin 6/JAK2 pathway is...
3.
Cohen E, Nabell L, Wong D, Day T, Daniels G, Milhem M, et al.
Clin Cancer Res
. 2021 Dec;
28(6):1157-1166.
PMID: 34965944
Purpose: To determine whether SD-101, a Toll-like receptor 9 agonist, potentiates the antitumor activity of anti-PD-1 antibodies in patients with anti-PD-1/PD-L1 naïve, recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)....
4.
Chesney J, Awasthi S, Curti B, Hutchins L, Linette G, Triozzi P, et al.
Melanoma Res
. 2017 Nov;
28(1):44-51.
PMID: 29176501
Talimogene laherparepvec is a genetically modified herpes simplex virus-1-based oncolytic immunotherapy for the local treatment of unresectable cutaneous, subcutaneous, and nodal tumors in patients with melanoma recurrence following surgery. We...
5.
Hallmeyer S, Gonzalez R, Lawson D, Cranmer L, Linette G, Puzanov I, et al.
Melanoma Res
. 2017 Oct;
27(6):585-590.
PMID: 29076950
BRAF mutations are found in ~50% of metastatic melanomas, most commonly in codon V600. Vemurafenib improves progression-free survival and overall survival in patients with advanced BRAF-mutated melanoma. The results of...
6.
Kaufman H, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, et al.
J Immunother Cancer
. 2016 Mar;
4:12.
PMID: 26981242
Background: We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), resulted in an objective response rate of 26 % in patients with advanced melanoma...
7.
Hughes M, Zager J, Faries M, Alexander H, Royal R, Wood B, et al.
Ann Surg Oncol
. 2015 Nov;
23(4):1309-19.
PMID: 26597368
Purpose: There is no consensus for the treatment of melanoma metastatic to the liver. Percutaneous hepatic perfusion with melphalan (PHP-Mel) is a method of delivering regional chemotherapy selectively to the...
8.
White Jr R, Ayers G, Stell V, Ding S, Gershenwald J, Salo J, et al.
Ann Surg Oncol
. 2011 Jun;
18(13):3593-600.
PMID: 21647761
Background: Numerous predictive factors for cutaneous melanoma metastases to sentinel lymph nodes have been identified; however, few have been found to be reproducibly significant. This study investigated the significance of...
9.
Bedikian A, Richards J, Kharkevitch D, Atkins M, Whitman E, Gonzalez R
Melanoma Res
. 2010 Apr;
20(3):218-26.
PMID: 20354459
Allovectin-7, a bicistronic plasmid encoding human leukocyte antigen-B7 and beta-2 microglobulin formulated with a cationic lipid system, is an immunotherapeutic agent designed to express allogeneic major histocompatibility complex class I...
10.
Senzer N, Kaufman H, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al.
J Clin Oncol
. 2009 Nov;
27(34):5763-71.
PMID: 19884534
Purpose: Treatment options for metastatic melanoma are limited. We conducted this phase II trial to assess the efficacy of JS1/34.5-/47-/granulocyte-macrophage colony-stimulating factor (GM-CSF) in stages IIIc and IV disease. Patients...